XETRA - Delayed Quote EUR

Abbott Laboratories (ABL.DE)

Compare
110.00
-0.88
(-0.79%)
At close: January 10 at 5:35:40 PM GMT+1
Loading Chart for ABL.DE
DELL
  • Previous Close 110.88
  • Open 110.22
  • Bid 110.52 x 69000
  • Ask 110.78 x 78000
  • Day's Range 109.78 - 111.54
  • 52 Week Range 90.00 - 114.14
  • Volume 143
  • Avg. Volume 480
  • Market Cap (intraday) 190.791B
  • Beta (5Y Monthly) 0.72
  • PE Ratio (TTM) 34.48
  • EPS (TTM) 3.19
  • Earnings Date Jan 22, 2025
  • Forward Dividend & Yield 2.25 (2.03%)
  • Ex-Dividend Date Jan 15, 2025
  • 1y Target Est --

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

www.abbott.com

114,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ABL.DE

View More

Performance Overview: ABL.DE

Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

ABL.DE
0.31%
S&P 500
1.35%

1-Year Return

ABL.DE
8.74%
S&P 500
22.51%

3-Year Return

ABL.DE
2.24%
S&P 500
24.59%

5-Year Return

ABL.DE
55.67%
S&P 500
77.94%

Compare To: ABL.DE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ABL.DE

View More

Valuation Measures

As of 1/9/2025
  • Market Cap

    192.13B

  • Enterprise Value

    199.10B

  • Trailing P/E

    34.76

  • Forward P/E

    22.17

  • PEG Ratio (5yr expected)

    2.22

  • Price/Sales (ttm)

    4.85

  • Price/Book (mrq)

    4.98

  • Enterprise Value/Revenue

    4.98

  • Enterprise Value/EBITDA

    19.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.99%

  • Return on Assets (ttm)

    6.49%

  • Return on Equity (ttm)

    14.84%

  • Revenue (ttm)

    41.22B

  • Net Income Avi to Common (ttm)

    5.74B

  • Diluted EPS (ttm)

    3.19

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.79B

  • Total Debt/Equity (mrq)

    37.59%

  • Levered Free Cash Flow (ttm)

    6.4B

Research Analysis: ABL.DE

View More

People Also Watch